Medication info

Piometar 15/850 mg Tablets

Prescription medicationTabletExpired
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Samsung Pharmaceutical Co., Ltd.
Appearance
White to grayish-white oblong film-coated tablets
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Expired

MFDS item code 201902844 · Approved 2019.05.02

This product's status changed to Expired on 2024.05.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of the individual components: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the dose of metformin or pioglitazone the patient is currently receiving. Start with 1 tablet of this medicine per day and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. No studies have been conducted to evaluate the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, use caution and ensure appropriate monitoring. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this medicine. After administering this medicine to a patient or increasing the dose, carefully monitor for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1C reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended, provided that glycemic control measured by FPG does not worsen.

Ingredients

Manufacturer
Samsung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Insulin-independent diabetes
  • abnormal blood sugar control
  • type 2 diabetes
View approved original text

This medication is used to improve blood sugar control in patients with insulin-independent diabetes, namely type 2 diabetes. It is particularly administered as an adjunct to dietary and exercise therapy to help effectively manage blood glucose levels. This medication may help when blood sugar control is insufficient with monotherapy using metformin or pioglitazone alone. Additionally, this medication may be used instead of a combination therapy with metformin and pioglitazone. Management of type 2 diabetes requires a multifaceted approach, including nutritional counseling, weight loss, and exercise, which are important not only for initial treatment but also for maintaining the effectiveness of medication therapy. This medication is effectively used to improve patients' blood sugar control.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of the individual components: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the dose of metformin or pioglitazone the patient is currently receiving. Start with 1 tablet of this medicine per day and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. No studies have been conducted to evaluate the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, use caution and ensure appropriate monitoring. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this medicine. After administering this medicine to a patient or increasing the dose, carefully monitor for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1C reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended, provided that glycemic control measured by FPG does not worsen.

Precautions

This medication helps to control blood sugar. However, during the use of this medication, there is a risk of a serious condition called lactic acidosis. Lactic acidosis is a rare but very dangerous condition caused by excessive lactate buildup in the body and can be life-threatening if not treated. The risk is particularly high in patients with impaired kidney function or with heart disease, as well as in cases of severe infections or dehydration. Therefore, it is essential to regularly monitor kidney and liver functions and to consult a physician promptly if any abnormal symptoms appear. Additionally, it is important to avoid excessive alcohol consumption while taking this medication. This medication can put a strain on the heart, so special caution is needed for patients with heart failure or a history of heart disease. If weight gain or symptoms of edema occur while taking the medication, it is important to inform a physician. Pregnant or nursing women should not take this medication, and caution is also needed in children and the elderly. Furthermore, there may be interactions when taking this medication with other drugs, so it is crucial to inform a physician of all medications being taken. In case of overdose, seek medical attention immediately for appropriate treatment. While taking this medication, it is important to regularly monitor blood sugar levels and conduct consistent assessments of kidney and liver functions to manage health status effectively.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 38 more
  • upper respiratory infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • exacerbation of diabetes
  • pharyngitis
  • anemia
  • liver failure
  • decreased vision
  • congestive heart failure
  • indigestion
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intestinal pneumatosis
  • increased serum creatinine
  • increased serum urea
  • macular edema
  • fracture
  • megaloblastic anemia
  • hypoglycemia
  • blood glucose abnormalities
  • gastroenteritis
  • failure of blood glucose control
  • urinary disorders
  • urgency
  • bladder cancer

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius. This will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

White to grayish-white oblong film-coated tablets

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.